Novonesis Reports Strong Sales Growth
Recently, Novonesis has announced an impressive 9% organic sales growth in the first half of the year. This positive development has also led to a revision of their full-year sales growth outlook, now projected in the range of 6-8%. The company’s growth can be attributed to strong demand for its biosolutions, showcasing resilience in a challenging economic environment.
Leadership's Optimism
Ester Baiget, the President and CEO of Novonesis, expressed enthusiasm about the results. She emphasized that the demand for their biosolutions remains robust despite global economic headwinds. Baiget announced the lifting of the lower end of the full-year guidance in response to sustained sales momentum. The company plans to continue significant investments to enhance its unique market position as it prepares for its next strategic phase extending to 2030.
Highlights from H1 Results
Several key points can be drawn from the results:
- Organic sales growth reached 9% for H1, with an 8% growth in Q2.
- Food & Health sector achieved a remarkable 10% organic sales growth, while Planetary Health recorded 9%.
- Emerging markets outpaced developed markets with organic sales growth figures of 12% compared to 8%.
- The company has achieved a 100% run rate in cost synergies, showing efficient operational integration.
- Adjusted EBITDA margin improved significantly to 37.4%, a rise of 210 basis points.
Financial Performance Overview
Looking deeper into the financials, Novonesis reported a 23% increase in adjusted net profit. Additionally, their net interest-bearing debt to EBITDA ratio stands at 2.1x, which reflects a strong balance sheet post the acquisition of a part of the Feed Enzyme Alliance.
Future Initiatives and Strategies
Novonesis also completed a EUR 100 million share buyback program, showcasing confidence in its long-term strategy and current share valuation. The revised outlook for 2025 now positions organic sales growth between 6-8%, while the adjusted EBITDA margin is anticipated to remain stable at 37-38% amidst ongoing currency fluctuations.
Dividends and Long-Term Goals
The company has approved an interim dividend of 2.25 DKK (approximately EUR 0.30) for the first half of the year, which is a positive indicator of their revenue stability. Looking ahead, Novonesis has articulated its financial goals aimed at 2030, focusing on maintaining a strong market presence and expanding within the biosolutions sector.
Upcoming Investor Engagement
The details of the 2030 strategy will be presented during a conference call marking the end of H1 2025. Stakeholders can expect an in-depth discussion on strategic priorities moving forward and insights on how Novonesis plans to sustain its growth trajectory.
Contact Information
For further inquiries, interested parties can reach out to the dedicated Investor Relations team:
Tobias Bjorklund, +45 3077 8682, tobb@novonesis.com
Anders Enevoldsen, +45 5350 1453, adev@novonesis.com
Katrine Spedtsberg Poulsen, kats@novonesis.com
Frequently Asked Questions
What sales growth did Novonesis achieve in H1?
Novonesis reported a notable 9% organic sales growth in the first half of the year.
What is the revised full-year sales growth outlook?
The full-year sales growth outlook has been narrowed to 6-8%.
Who is the CEO of Novonesis?
Ester Baiget serves as the President and CEO of Novonesis.
What key financial metrics improved for Novonesis?
Adjusted EBITDA margin increased to 37.4%, and net profit rose by 23%.
What are Novonesis's long-term goals?
The company has a strategic plan to strengthen its market position and invest significantly until 2030.
